Recurrent and Refractory Ewing Sarcoma Phase I/II Trials: Current Perspective From the Euro-Ewing Consortium
Dose-intensive chemotherapy with vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide is more effective, less toxic, and shorter in duration for all stages of newly diagnosed Ewing sarcoma than vincristine, ifosfamide, doxorubicin, and etoposide induction and should now be the standard of care for Ewing sarcoma.
Evidence level: Irányelv / elfogadott gyakorlat. Magas szintű klinikai elfogadottság.
Related signals
- Revisiting CDKN2A dysregulation in Ewing sarcoma
- Emerging therapies in Ewing sarcoma
- Genome‑wide association study meta‑analysis identifies susceptibility loci informing Ewing sarcoma etiology and potential mechanisms of risk
- Biochemists discover new strategy to combat pediatric bone cancer
- Integrated Immunotherapy Target Atlas for Ewing Sarcoma